Opioid Use Disorder and the Covid 19 Pandemic: A Call to Sustain Regulatory Easements and Further Expand Access to Treatment
- 1 April 2020
- journal article
- editorial
- Published by SAGE Publications in Substance Abuse
- Vol. 41 (2) , 147-149
Abstract
We highlight the critical roles that pharmacists have related to sustaining and advancing the changes being made in the face of the current COVID-19 pandemic to ensure that patients have more seamless and less complex access to treatment. Discussed herein is how the current COVID-19 pandemic is impacting persons with substance use disorders, barriers that persist, and the opportunities that arise as regulations around treatments for this population are eased.Keywords
This publication has 16 references indexed in Scilit:
- Promising roles for pharmacists in addressing the U.S. opioid crisisResearch in Social and Administrative Pharmacy, 2019
- Buprenorphine Deregulation and Mainstreaming Treatment for Opioid Use DisorderJAMA Psychiatry, 2019
- Methadone in Primary Care — One Small Step for Congress, One Giant Leap for Addiction TreatmentNew England Journal of Medicine, 2018
- No End to the Crisis without an End to the WaiverSubstance Abuse, 2018
- Opioid misuse epidemic: Addressing opioid prescribing and organization initiatives for holistic, safe and compassionate careNursing Outlook, 2017
- Advanced Practice Nurses: Increasing Access to Opioid Treatment by Expanding the Pool of Qualified Buprenorphine PrescribersSubstance Abuse, 2015
- Immediate Impact of Hurricane Sandy on People Who Inject Drugs in New York CitySubstance Use & Misuse, 2015
- Effects of Regulation on Methadone and Buprenorphine Provision in the Wake of Hurricane SandyJournal of Urban Health, 2014
- Legal Challenges for Substance Abuse Treatment During DisastersPsychiatric Services, 2012
- Impact of supervision of methadone consumption on deaths related to methadone overdose (1993-2008): analyses using OD4 index in England and ScotlandBMJ, 2010